Firm's Cannabis Flower Yield Surpasses Expectations
Source: Streetwise Reports  (7/29/19)
Also, the company begins growing a second strain. More >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal
Source: Streetwise Reports  (7/29/19)
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. More >

Catasys: This Is Bigger Than You Think
Source: Daniel Carlson for Streetwise Reports  (7/26/19)
Daniel Carlson of Tailwinds Research examines the "blockbuster" implications of a recent announcement about this company's OnTrak program. More >

eHealth Shares Up 25% as Quarterly Revenue Doubled and 2019 Guidance Raised
Source: Streetwise Reports  (7/26/19)
The prognosis for online exchange operator eHealth Inc. looks positive as the company reported a 101% increase in Q2/19 revenues over the prior year period and raised full year 2019 revenue estimates by $50 million to $365–385 million, compared with previous guidance of $315–335 million for 2019. More >

Align Technology Reports Strong Q2 Growth but China Sales Worries Leave Investors Frowning
Source: Streetwise Reports  (7/25/19)
Orthodontic and GP Dental medical device maker Align Technology announced a 24.6% increase in sales volume of its Invisalign products in its Q2/19 earnings report, but investors are not smiling much over China growth concerns as the shares of the company have fallen more than 25%. More >

Anixa Licenses Another Potential Blockbuster
Source: Daniel Carlson for Streetwise Reports  (7/24/19)
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. More >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report
Source: Streetwise Reports  (7/24/19)
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. More >

Biotech Firm ''Creating Innovative Solutions' for Female Health
Source: Streetwise Reports  (7/23/19)
The company's most advanced assets are discussed in a Dawson James Securities report. More >

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'
Source: Streetwise Reports  (7/23/19)
The immuno-oncology company's findings are reviewed in a ROTH Capital Partners report. More >

Biopharma's New License Agreement with Gilead 'Brings Strong Validation and Economics'
Source: Streetwise Reports  (7/23/19)
The specifics and benefits of the deal are discussed in an H.C. Wainwright & Co. report. More >

Biopharma Presents Data on Its Therapeutic Candidates at Alzheimer's Conference
Source: Streetwise Reports  (7/22/19)
The company discussed both its Alzheimer's disease and ALS programs. More >

Innovative Healthcare Firm Closes Two Pharmacy Acquisitions
Source: Streetwise Reports  (7/22/19)
These assets complement the company's primary care clinics and telemedicine and electronic medical record functionality. More >

Biopharma Licenses Sustained Release Technology to Gilead for HIV Product
Source: Streetwise Reports  (7/22/19)
The two California-based companies will collaborate on specific related development activities. More >

California Gold Building Hemp Seed Propagation Greenhouse in Illinois
Source: Peter Epstein for Streetwise Reports  (7/22/19)
Peter Epstein of Epstein Research checks into the most recent developments announced by this company, which include planting 130,000 hemp plantlets on 40 acres. More >

Biopharma Receives PDUFA Goal Date for Nonopioid Pain Drug
Source: Streetwise Reports  (7/18/19)
The FDA deemed the firm's submission for analgesic approval complete. More >

Biotech Demonstrates Superiority of Polyp-Detecting Product
Source: Streetwise Reports  (7/17/19)
The study results and their meaning are reviewed in an H.C. Wainwright & Co. report. More >

Top Pick Status Given to Small-Cap with Pain Drug Candidate
Source: Streetwise Reports  (7/17/19)
The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. More >

Biotech Incorporates Urologists' Feedback Into Device Design
Source: Streetwise Reports  (7/17/19)
This step moves the product further down the development track. More >

Canadian Firm to Sell THC Cannabis Oil-Filled Capsules
Source: Streetwise Reports  (7/17/19)
The product will be launched under its brand for the recreational market. More >

Seattle Genetics Shares Head Higher After Positive Earnings and ADCETRIS Sales Expansion
Source: Streetwise Reports  (7/17/19)
Seattle Genetics announced a 28.3% increase in net sales for its second quarter 2019 powered by ADCETRIS sales along with a promising pipeline. More >

Biopharma's Brain Cancer Therapeutic Compelling, Its Stock Undervalued
Source: Streetwise Reports  (7/16/19)
A description of the asset and its potential are provided in a Dawson James report. More >

Logistics Firm Expands Into Another Cannabis Industry Segment
Source: Streetwise Reports  (7/16/19)
Its newly entered agreement offers potential for future growth in Canada. More >

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead
Source: Streetwise Reports  (7/15/19)
Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. More >

Technical Analyst: Medical Device Stock Looking Set to Reverse
Source: Clive Maund for Streetwise Reports  (7/12/19)
Technical analyst Clive Maund charts the stock of this company that has developed a device that uses a special light that visualizes cancer during minimally invasive surgery. More >

Illumina Shares Fall Sharply on Lower Revenue Guidance
Source: Streetwise Reports  (7/12/19)
Illumina Inc. shares traded down more than 15% as the company reported lower preliminary Q2/19 revenues and updated its annual revenue guidance. More >